Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Jonathan Biller Sells 945 Shares

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Jonathan Biller sold 945 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $459,600.75. Following the completion of the transaction, the executive vice president owned 13,659 shares of the company’s stock, valued at approximately $6,643,054.65. This trade represents a 6.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jonathan Biller also recently made the following trade(s):

• On Wednesday, February 11th, Jonathan Biller sold 1,925 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $460.43, for a total value of $886,327.75.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $480.13 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.68. The company has a 50 day simple moving average of $465.74 and a two-hundred day simple moving average of $431.13. The company has a market capitalization of $121.97 billion, a PE ratio of 31.32 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same quarter in the previous year, the firm earned $3.98 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 9.5% on a year-over-year basis. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on VRTX shares. Wolfe Research upgraded shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 target price for the company in a research note on Tuesday, January 6th. Royal Bank Of Canada lowered their target price on Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a research note on Friday, February 13th. Wells Fargo & Company increased their price target on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. UBS Group lifted their price objective on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Evercore upped their price target on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Twenty-two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $542.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Motiv8 Investments LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $26,000. Access Investment Management LLC bought a new stake in shares of Vertex Pharmaceuticals in the second quarter worth about $27,000. Swiss RE Ltd. purchased a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $28,000. Chesapeake Asset Management LLC raised its holdings in Vertex Pharmaceuticals by 110.0% in the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 33 shares in the last quarter. Finally, Eagle Bay Advisors LLC purchased a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $29,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: CEO Reshma Kewalramani profiled by TIME as a physician-scientist running one of biotech’s largest companies — positive PR that supports confidence in leadership and long-term strategy. Physician-Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Coverage asking whether VRTX is outperforming the Dow highlights recent relative strength and investor interest in Vertex’s growth profile — supports demand from momentum/quality investors. Is Vertex Stock Outperforming the Dow?
• Neutral Sentiment: Analyst/market commentary pieces (e.g., Nasdaq‑100 roundup) raise attention but are mixed in tone and not specific to new catalysts for Vertex. 2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
• Neutral Sentiment: Recent Q4 results (reported Feb. 12) showed revenue growth (~+9.5% y/y) and margin strength but a very slight EPS miss (reported $5.03 vs. $5.05 consensus). Fundamentals remain solid, but the tiny miss tempers upside catalysts in the near term.
• Negative Sentiment: Multiple insider sales disclosed in SEC filings — including a large sale by EVP Amit Sachdev (58,613 shares sold, ~$27.5M) and several sales by other executives on Feb. 25 — may be weighing on the stock as investors interpret reduced insider holdings as a negative signal (though sales can reflect diversification or tax planning). Representative SEC filing: SEC Form 4 – Amit Sachdev

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.